This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051
and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK),
preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic
castration-resistant prostate cancer who have progressed despite prior therapy and had been
treated with at least one potent anti-androgen therapy.
The starting dose, 25 mg once daily (QD), of FT-7051 administered discontinuously (21 days
on/7 days off) in 28-day cycles.